Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are assessing the long-term safety of subcutaneous guselkumab in children with moderate to severe ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3, open-label study enrolls pediatric participants who previously received guselkumab in one of three primary studies and are considered by their investigator to benefit from continued treatment. The study aims to monitor safety over an extended period to better understand the effects of ongoing guselkumab use in these conditions. Participants who completed dosing in the primary studies will continue guselkumab treatment in this long-term extension study. Dosing schedules include injections every 8 weeks or every 4 weeks, depending on their original study arm and clinical status. Some participants may switch dosing intervals once during the study before unblinding, while others will maintain their initial regimen. The study allows continued access to guselkumab over the long term, with dosing adjustments guided by prior treatment plans and investigator discretion. Throughout the study, participants will be closely monitored for treatment-emergent adverse events for up to 6 years and 9 months. Assessments will include regular evaluations by investigators to ensure safety and adherence. Parents or legal representatives consent for children to participate, with assent obtained from capable participants aged 7 years and older. The study emphasizes long-term safety tracking and maintaining participant well-being during extended guselkumab therapy.
Actively Recruiting
Researchers are evaluating the effect of E6742, an oral drug, compared with a placebo in adults with systemic lupus erythematosus SLE. This phase 2, randomized, double-blind, placebo-controlled study aims to assess how different doses of E6742 influence the proportion of participants achieving a response using the British Isles Lupus Assessment Group BILAG based Composite Lupus Assessment BICLA while using a low dose of oral corticosteroids at Week 24. Participants will be randomly assigned to receive one of several doses of E6742 or a placebo in oral tablet form. The treatment period involves administering these doses while monitoring participants for up to 24 weeks. The study evaluates the efficacy based on dose response, as well as safety measures including adverse events, laboratory tests, vital signs, and various clinical assessments during this time. Throughout the study, participants will undergo multiple evaluations including clinical assessments like SLEDAI-2K, BILAG-2004, patient-reported outcomes, and laboratory tests such as autoantibody levels and complements. Safety will be monitored via vital signs, ECGs, ophthalmic exams, and chest X-rays. The primary outcome is measured at Week 24, with safety and secondary outcomes assessed up to 52 weeks. Participants are expected to comply with study visits and treatments over this period.
Actively Recruiting
Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.
Actively Recruiting
Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.
Actively Recruiting
Researchers are studying risankizumab, a drug approved for adults with certain conditions, to evaluate its effects in children aged 2 to under 18 years with moderately to severely active Crohns Disease who have not responded well or are intolerant to other treatments. This Phase 3 study includes three groups by age and involves multiple study parts to assess how the drug moves through the body, its safety, and its impact on disease activity. Participants will receive risankizumab through an intravenous infusion during a 12-week induction phase. Those who complete this phase may enter a 52-week maintenance period where they receive one of two doses of the drug by subcutaneous injection without knowing which dose they get. Afterward, participants can join a 208-week open-label extension phase with risankizumab dosing based on their previous response. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, and questionnaires will be used to monitor disease activity and check for side effects. Key measures include clinical remission and endoscopic response at 12 and 64 weeks. Follow-up continues for about 140 days after treatment periods, allowing researchers to understand the drugs effects and safety over time.
Actively Recruiting
Researchers are evaluating the efficacy, safety, pharmacokinetics PK, and pharmacodynamics PD of atumelnant in adults with classic congenital adrenal hyperplasia CAH caused by 21-hydroxylase deficiency 21-OHD. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 18 to under 75 years who have been on a stable glucocorticoid GC regimen for at least 2 months. The study aims to understand how atumelnant works and how safe it is for this population. Participants will be randomly assigned in a 21 ratio to receive either atumelnant tablets or a matching placebo once daily for 32 weeks. The atumelnant dose starts at 80 mg daily with an option to increase to 120 mg daily at Week 20 if needed. Before treatment, participants undergo a 3- to 6-week screening period to confirm eligibility. Approximately 150 participants may take part worldwide. During the study, participants will have regular assessments including hormone level measurements such as morning post-GC androstenedione A4 to evaluate response. Researchers will monitor glucocorticoid doses, safety, and other health indicators. The main outcome is the proportion of participants achieving morning post-GC A4 levels at or below the upper limit of normal while on physiologic GC replacement at Week 32. The total participation time includes screening plus 32 weeks of treatment and evaluations.
Actively Recruiting
Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. Asthma is a condition that makes breathing difficult and affects quality of life. This phase 2 clinical trial includes participants aged 18 to 75 who have had moderate-to-severe asthma for at least 12 months and have been on maintenance asthma treatment for the past 6 months. Participants will receive either PF-07275315 or a placebo, both given as multiple subcutaneous injections in the clinic over 12 weeks. The study compares experiences between those receiving the study medicine and those receiving placebo to assess safety and effects. The trial is randomized, double-blind, and placebo-controlled with parallel groups. During the study, participants will be involved for up to approximately 9.5 months depending on local regulations. They will have regular visits for injections and assessments including lung function tests like FEV1, questionnaires about asthma control and quality of life, and safety monitoring through lab tests, vital signs, and electrocardiograms. Researchers will track changes from baseline in lung function and adverse events up to 24 weeks after treatment begins.
Actively Recruiting
This research aims to evaluate how the drug Risankizumab works in children with moderate to severe ulcerative colitis UC, a disease causing inflammation and bleeding in the colon and rectum. The study focuses on pediatric participants aged 2 to under 18 years and assesses the drugs safety, how it moves through the body, and its impact on disease activity. The trial is sponsored by AbbVie and includes multiple groups based on age ranges. Participants will be divided into three cohorts by age 6 to under 18 years, 2 to under 6 years, and 2 to under 18 years. The study has three substudies an open-label induction phase lasting 12 weeks with intravenous Risankizumab a 52-week randomized, double-blind maintenance phase with subcutaneous Risankizumab at two different doses and a 208-week open-label extension where participants receive Risankizumab based on their response in the maintenance phase. During the trial, participants will attend regular hospital or clinic visits where medical assessments, blood tests, and questionnaires will monitor treatment effects and side effects. The study measures include drug concentration in the blood, clinical remission, symptom improvement, and adverse events. Follow-up continues for about 140 days after treatment to ensure safety and evaluate long-term outcomes.
Actively Recruiting
Researchers are evaluating the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab infusion compared with placebo in children aged 5 to under 18 years with moderate to severe active systemic lupus erythematosus SLE who are on standard background therapy. This phase III study aims to better understand how anifrolumab works and its effects in pediatric SLE patients. Participants are randomly assigned to receive either anifrolumab or a matching placebo via intravenous infusion every 4 weeks. The study includes multiple periods a screening period up to 30 days Part A, a four-week double-blind, placebo-controlled pharmacokinetic phase Part B, a double-blind, placebo-controlled safety and efficacy phase lasting 48 to 52 weeks depending on prior participation Part C, a 52-week open-label extension and Part D, a safety follow-up with one visit 12 weeks after the last dose. During the study, participants undergo various assessments including blood tests to measure drug levels, immune markers, and disease activity using specific lupus assessment tools. Researchers monitor response to treatment, safety, and changes in corticosteroid use over time. The total participation lasts about 116 weeks, with scheduled visits for infusions and evaluations to track disease progress and treatment effects.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of TEV-56286, an oral drug, for adults with Multiple System Atrophy MSA. This Phase 2 trial aims to observe how well participants tolerate the medication over an extended period and to further describe its safety profile. The study is sponsored by Teva Branded Pharmaceutical Products R&D LLC and plans to include participants aged 30 and older. Participants in the trial will receive TEV-56286 orally throughout the study. This open-label extension trial follows up on a previous double-blind trial, focusing on continued treatment and monitoring. The total planned duration for participant involvement is approximately 100 weeks, allowing for long-term observation of safety and tolerability. During the study, participants will undergo regular assessments to monitor adverse events, vital signs, laboratory test results including hematology and chemistry, and 12-lead ECG measurements. Researchers will track any side effects and reasons for withdrawal throughout the 100-week period. The trial includes safety follow-up visits and aims to collect comprehensive data on the long-term effects of TEV-56286 in adults with MSA.
1-10 of 25
1